脾脏组织细胞肉瘤1例
A Case Report: Histiocytic Sarcoma of the Spleen
DOI: 10.12677/jcpm.2026.53180, PDF,   
作者: 龙思妤, 邱佳慧:暨南大学第一临床医学院,广东 广州;沈 思*:暨南大学附属第一医院,广州华侨医院,放射科,广东 广州
关键词: 组织细胞肉瘤脾肿瘤计算机体层成像病理学Histiocytic Sarcoma Spleen Neoplasms Computed Tomography Pathology
摘要: 本文报道一例67岁女性脾组织细胞肉瘤患者的影像学及病理学特征,旨在提高对该罕见病的认识和诊断。患者因体检发现脾占位伴左腰部隐痛就诊。腹部CT表现为脾内巨大混杂密度肿块,增强后边缘及分隔呈进行性强化,术前影像易误诊为良性肿瘤。最终经脾切除术后的病理学检查确诊:镜下见显著异型性的梭形/上皮样细胞,免疫组化显示CD68、CD163弥漫强阳性,Ki-67指数达30%。本例说明,脾组织细胞肉瘤的CT表现虽可提示恶性,但缺乏特异性,极易误诊,病理学及免疫组化是确诊该病的金标准。
Abstract: This article presents the imaging and pathological features of a case of splenic histiocytic sarcoma in a 67-year-old female to enhance recognition of this rare entity. The patient presented with a splenic mass discovered incidentally during a physical examination, accompanied by dull pain in the left lumbar region. Abdominal CT revealed a large, heterogeneous-density mass within the spleen, which demonstrated progressive enhancement of the periphery and internal septa on post-contrast images; these imaging findings were prone to preoperative misdiagnosis as a benign tumor. The diagnosis was confirmed by pathological examination following splenectomy, which revealed spindle/epithelioid cells with significant atypia. Immunohistochemistry showed diffuse and strong positivity for CD68 and CD163, with a Ki-67 proliferation index of 30%. This case illustrates that while CT findings of splenic histiocytic sarcoma may suggest malignancy, they are non-specific and carry a high risk of misdiagnosis. Pathological examination combined with immunohistochemical analysis remains the gold standard for definitive diagnosis.
文章引用:龙思妤, 邱佳慧, 沈思. 脾脏组织细胞肉瘤1例[J]. 临床个性化医学, 2026, 5(3): 33-37. https://doi.org/10.12677/jcpm.2026.53180

参考文献

[1] Kommalapati, A., Tella, S.H., Durkin, M., Go, R.S. and Goyal, G. (2018) Histiocytic Sarcoma: A Population-Based Analysis of Incidence, Demographic Disparities, and Long-Term Outcomes. Blood, 131, 265-268. [Google Scholar] [CrossRef] [PubMed]
[2] Sabattini, E., Bacci, F., Sagramoso, C., et al. (2010) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2008: An Overview. Pathologica, 102, 83-87.
[3] Kobayashi, S., Kimura, F., Hama, Y., Ogura, K., Torikai, H., Kobayashi, A., et al. (2008) Histiocytic Sarcoma of the Spleen: Case Report of Asymptomatic Onset of Thrombocytopenia and Complex Imaging Features. International Journal of Hematology, 87, 83-87. [Google Scholar] [CrossRef] [PubMed]
[4] Egan, C., Nicolae, A., Lack, J., Chung, H., Skarshaug, S., Pham, T.A., et al. (2019) Genomic Profiling of Primary Histiocytic Sarcoma Reveals Two Molecular Subgroups. Haematologica, 105, 951-960. [Google Scholar] [CrossRef] [PubMed]
[5] Peng, Y.J. and He, Y.Q. (2024) Histiocytic Sarcoma of the Spleen without Thrombocytopenia. Revista Española de Enfermedades Digestivas, 116, 703-704. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, F., Jin, H.F., Fan, Y.H., Cai, L.J., Zhang, Z.Y. and Lv, B. (2015) Case Report of Primary Splenic Angiosarcoma with Hepatic Metastases. World Journal of Gastroenterology, 21, 11199-11204. [Google Scholar] [CrossRef] [PubMed]
[7] Gan, M., He, X. and Zheng, X. (2024) FDG PET/CT Imaging of Liver and Spleen Histiocytic Sarcoma. Clinical Nuclear Medicine, 49, 272-273. [Google Scholar] [CrossRef] [PubMed]
[8] Valizadeh, P., Jannatdoust, P., Tahamtan, M., Soleimani Dorcheh, S., Khalaj, F., Ghorani, H., et al. (2024) Differentiating Malignant from Benign Splenic Lesions: A Meta-Analysis and Pictorial Review of Imaging Features. Abdominal Radiology, 49, 2833-2857. [Google Scholar] [CrossRef] [PubMed]
[9] Harwood, M., Craig, F.E. and Yang, M. (2021) Rare Multisystem Histiocytic Sarcoma on 18f-FDG PET/CT. Journal of Nuclear Medicine Technology, 49, 358-359. [Google Scholar] [CrossRef] [PubMed]
[10] Hung, Y.P. and Qian, X. (2020) Histiocytic Sarcoma. Archives of Pathology & Laboratory Medicine, 144, 650-654. [Google Scholar] [CrossRef] [PubMed]
[11] Kramer, P., Prins, M.E.F., Kapsenberg, J.G., Bornkamm, G.W., Bijnen, A.B., Rohol, P.J.M., et al. (1985) Persistent Epstein-Barr Virus Infection and a Histiocytic Sarcoma in a Renal Transplant Recipient. Cancer, 55, 503-509. [Google Scholar] [CrossRef] [PubMed]
[12] Durham, B.H., Diamond, E.L. and Abdel-Wahab, O. (2016) Histiocytic Neoplasms in the Era of Personalized Genomic Medicine. Current Opinion in Hematology, 23, 416-425. [Google Scholar] [CrossRef] [PubMed]
[13] Koh, K.N., Yoon, S.H., Kang, S.H., Kim, H. and Im, H.J. (2024) Advancements in the Understanding and Management of Histiocytic Neoplasms. Blood Research, 59, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[14] Ozkaya, N., Dogan, A. and Abdel-Wahab, O. (2017) Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Hematology/Oncology Clinics of North America, 31, 705-719. [Google Scholar] [CrossRef] [PubMed]
[15] Cohen Aubart, F., Emile, J., Maksud, P., Galanaud, D., Cluzel, P., Benameur, N., et al. (2018) Efficacy of the MEK Inhibitor Cobimetinib for Wild‐Type BRAF Erdheim‐Chester Disease. British Journal of Haematology, 180, 150-153. [Google Scholar] [CrossRef] [PubMed]